New therapies for patients with multiple endocrine neoplasia type 1

• Published in: Annales d'endocrinologie 2021-04, Vol.82 (2), p.112-120
• Main Authors: Geslot, Aurore, Vialon, Magaly, Caron, Philippe, Grunenwald, Solange, Vezzosi, Delphine
• Format: Article
• Language: English
• Subjects: Adénome hypophysaire; Duodenopancreatic neuroendocrine tumor; Hyperparathyroïdie primaire; Multiple endocrine neoplasia type 1; Néoplasie endocrinienne multiple de type 1; Pituitary adenoma; Primary hyperparathyroidism; Tumeur neuroendocrine duodéno-pancréatique
• ISSN: 0003-4266
• DOI: 10.1016/j.ando.2021.03.005

In 1953, for the first time, Paul Wermer described a family presenting endocrine gland neoplasms over several generations. The transmission was autosomal dominant and the penetrance was high. Forty years later in 1997, the multiple endocrine neoplasia type 1 (MEN1) gene was sequenced, thus enabling diagnosis and early optimal treatment. Patients carrying the MEN1 gene present endocrine but also non-endocrine tumors. Parathyroid, pancreatic and pituitary impairment are the three main types of endocrine involvement. The present article details therapeutic management of hyperparathyroidism, neuroendocrine pancreatic tumors and pituitary adenomas in patients carrying the MEN1 gene. Significant therapeutic progress has in fact been made in the last few years. As concerns the parathyroid glands, screening of family members and regular monitoring of affected subjects now raise the question of early management of parathyroid lesions and optimal timing of parathyroid surgery. As concerns the duodenum-pancreas, proton-pump inhibitors are able to control gastrin-secreting syndrome, reducing mortality in MEN1 patients. Mortality in MEN1 patients is no longer mainly secondary to uncontrolled hormonal secretion but to metastatic (mainly pancreatic) disease progression. Tumor risk requires regular monitoring of morphological assessment, leading to iterative pancreatic surgery in a large number of patients. Finally, pituitary adenomas in MEN1 patients are traditionally described as aggressive, invasive and resistant to medical treatment. However, regular pituitary screening showed them to be in fact infra-centimetric and non-secreting in the majority of patients. Consequently, it is necessary to regularly monitor MEN1 patients, with regular clinical, biological and morphological work-up. Several studies showed that this regular monitoring impairs quality of life. Building a relationship of trust between patients and care provider is therefore essential. It enables the patient to be referred for psychological or psychiatric care in difficult times, providing long-term support and preventing any breakdown in continuity of care. En 1953, Paul Wermer décrivit pour la première fois une famille présentant, sur plusieurs générations, des tumeurs de glandes endocrines. La transmission était autosomique dominante et la pénétrance était élevée. Quarante ans plus tard, en 1997, le gène de la néoplasie endocrinienne multiple de type 1 (NEM1) fut séquencé, permettant ainsi un diagnost